June #113 : How to Treat "Untreatable" HIV

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

Fighting Femmes

The amfAR's new clothes

Warm Reception

White Smoke In Our Eyes

Hepatitis on the Block

High On Adherence

A Positive Campaign

Founder's Letter

Earthwatch: Generic Meds

On The March!

MILESTONES

THE PLOTS SICKEN

POZ Picks Gay Pride

Medi - Mess

How to Treat "Untreatable" HIV

Read It Or Weep

Live and Let Die?

Did Common Just Come Out?

Legal Eye

Quick Study

Why.....

Book nook

Mailbox

When Push Comes To Drag



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

June 2005

How to Treat "Untreatable" HIV

From last winter’s media frenzy, you’d think the New York City man infected with the highly resistant, very aggressive strain of HIV—dubbed the “supervirus”—had run out of treatment hopes before he’d begun. But a careful reading of his test results—especially his resistance profile—revealed to his savvy Aaron Diamond AIDS Research Center (ADARC) doctors that even a supervirus has weaknesses that current HIV meds can exploit.

CD4 Count: 39 
Below 200—an AIDS diagnosis. Given the short time he’s been infected, such quick progression requires immediate treatment.

Viral Load: 280,000
High—might need meds even if he had more CD4s.

Viral Fitness (Replication Capacity): 165%
Resistance usually makes HIV less fit. A replication capacity (RC) 65% greater than nonresistant, wild-type HIV bucks the trend. 

Resistance Profile—22 mutations:

Nukes: Broad resistance, but some sensitivity to a few.
The mutations cause much nuke resistance, but it’s not all or nothing. Docs chose Viread and Videx, to which he had some sensitivity.

Non-Nukes: No K103N mutation; resistant to Viramune and Rescriptor; partially sensitive to Sustiva.
The lack of K103N, which causes cross-resistance to the entire class, is a break. The docs chose Sustiva.

Protease Inhibitors (PIs): Resistance to all.
The many PI mutations suggest that the entire powerful class is lost to him, because PI cross-resistance is so common. But as Cal Cohen, MD, of the Community Research Initiative of New England, says, both tipranavir and TMC 114, experimental PIs with unique resistance profiles, may serve should this combo tank.

Entry Inhibitors (EIs): No resistance.
The sole approved EI, Fuzeon, isn’t widely used, so it’s no surprise that he has no resistance. The docs fingered Fuzeon as the combo cornerstone. It seems potent against resistant HIV when teamed with another active drug—in this case, Sustiva.

Prognosis: After two months, the nukes-plus-Sustiva-and-Fuzeon combo was showing considerable, if incomplete, control of the virus. While the man remains seriously ill, he has grounds for hope. POZ wishes him success and hopes he has found the support and empowerment available in the AIDS community—far from the doom-and-gloom headlines and hype. 





[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
Starting Treatment
Search for the Cure
POZ Stories
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar


    dlw8585
    Fort Lauderdale
    Florida


    slimcuteguy
    Asheville
    North Carolina


    OahuAJ
    Turlock
    California


    clintonjrsyr
    syracuse
    New York
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Can social media help stop HIV stigma?
Yes
No

Survey
Mind Matters

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.